Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 291 articles:
HTML format



Single Articles


    January 2022
  1. ZHANG Y, Yang M, Huang X, Yang H, et al
    Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2022 Jan 8. doi: 10.1111/jvh.13641.
    PubMed    


  2. PAN YC, Jia ZF, Wu YH, Lv HY, et al
    Response to comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2022 Jan 6. doi: 10.1111/jvh.13642.
    PubMed    


    December 2021
  3. ZHOU Y, Li J, Gordon SC, Trudeau S, et al
    Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States.
    J Viral Hepat. 2021 Dec 14. doi: 10.1111/jvh.13639.
    PubMed     Abstract available


  4. WANG XD, Pan CW, Zhou GY, Gao F, et al
    Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study.
    J Viral Hepat. 2021 Dec 13. doi: 10.1111/jvh.13640.
    PubMed     Abstract available


    November 2021
  5. MANDEL E, Peci A, Cronin K, Capraru CI, et al
    The Impact of the First, Second, and Third Waves of COVID-19 on Hepatitis B and C Testing in Ontario, Canada.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13637.
    PubMed     Abstract available


  6. GIADANS CG, Rios DA, Ameigeiras B, Haddad L, et al
    Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13635.
    PubMed     Abstract available


  7. LEMOINE M, Ndow G, Shimakawa Y
    Improving disease knowledge is critical to eliminate hepatitis B.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13633.
    PubMed     Abstract available


  8. FORNS X, Colom J, Garcia-Retortillo M, Quer JC, et al
    Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13634.
    PubMed     Abstract available


  9. MOHAMED EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, et al
    Electronic Nose versus Quadrupole Mass Spectrometry for Identifying Viral Hepatitis C Patients.
    J Viral Hepat. 2021 Nov 12. doi: 10.1111/jvh.13630.
    PubMed     Abstract available


  10. CHIDWICK K, Myton R, Rodgers A, Jun M, et al
    A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13629.
    PubMed     Abstract available


  11. JO AJ, Choi WM, Kim HJ, Choi SH, et al
    A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study.
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13631.
    PubMed     Abstract available


  12. CHANG HL, Wen WH, Lee CN, Chiu YE, et al
    Kinetics of Hepatitis B Surface Antigen in Pregnant Women with and without Tenofovir Disoproxil Fumarate.
    J Viral Hepat. 2021 Nov 1. doi: 10.1111/jvh.13628.
    PubMed     Abstract available


    October 2021
  13. JUGNARAIN DV, Halford R, Smith S, Hickman M, et al
    Role of peer support in a hepatitis C elimination program.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13626.
    PubMed     Abstract available


  14. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Serum alpha-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13625.
    PubMed     Abstract available


  15. RAMIREZ MENA A, Tine JM, Fortes L, Ndiaye O, et al
    Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal.
    J Viral Hepat. 2021 Oct 5. doi: 10.1111/jvh.13615.
    PubMed     Abstract available


  16. ZHOU Y, Lu Z, He H, Yan R, et al
    Influencing factors and necessity of post-vaccination serologic testing follow-up for HBsAg-positive mothers and their infants: A 5-year prospective study in Zhejiang Province, China (2016-2020).
    J Viral Hepat. 2021;28:1413-1421.
    PubMed     Abstract available


    September 2021
  17. NISHIGUCHI J, McNamara A, Surlyn CS, Eagen KV, et al
    Efficacy of an eConsult Service to Cure Hepatitis C in Primary Care.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13616.
    PubMed     Abstract available


  18. COPPOLA C, Masarone M, Bartoli M, Staiano L, et al
    Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13623.
    PubMed     Abstract available


  19. STROFFOLINI T, Morisco F, Ferrigno L, Pontillo G, et al
    Acute Delta Hepatitis in Italy spanning three decades (1991-2019): evidence for the effectiveness of the hepatitis B vaccination campaign.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13620.
    PubMed     Abstract available


  20. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Letter in response: Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13619.
    PubMed     Abstract available


  21. RODER C, Nguyen P, Harvey C, Wardrop M, et al
    Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13622.
    PubMed     Abstract available


  22. ROSATO V, Ascione A, Nevola R, Fracanzani AL, et al
    Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617.
    PubMed     Abstract available


  23. SOHN W, Chang Y, Cho YK, Hong YS, et al
    Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13618.
    PubMed     Abstract available


  24. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
    Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
    PubMed     Abstract available


  25. KOUTSIANAS C, Hadziyannis E, Thomas K, Deutsch M, et al
    Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents.
    J Viral Hepat. 2021 Sep 8. doi: 10.1111/jvh.13610.
    PubMed     Abstract available


  26. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
    Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
    PubMed     Abstract available


  27. DOUMBIA M, Sevede D, Kouakou V, Kouakou C, et al
    Viral and bacterial factors of mother-to-child transmission of hepatitis B virus.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13607.
    PubMed     Abstract available


  28. HAMDIUI N, van Steenbergen J, Rocha LEC, Meiberg A, et al
    Hepatitis B screening among immigrants: how to successfully reach the Moroccan community.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13604.
    PubMed     Abstract available


  29. CHEUNG KW, Seto MTY, Tsui PM, So PL, et al
    Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13609.
    PubMed     Abstract available


  30. ERKEN R, Andre P, Roy E, Kootstra N, et al
    Farnesoid X receptor agonist for the treatment of chronic hepatitis B; a safety study.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13608.
    PubMed     Abstract available


  31. GARCIA-CEHIC D, Rando A, Rodriguez-Frias F, Gregori J, et al
    Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    J Viral Hepat. 2021;28:1319-1324.
    PubMed     Abstract available


    August 2021
  32. TSAI HJ, Chuang YW, Yang SS, Chang YZ, et al
    Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
    J Viral Hepat. 2021 Aug 31. doi: 10.1111/jvh.13603.
    PubMed     Abstract available


  33. WANG L, Zhao J, Liu J, Zhen C, et al
    Long-term benefits of interferon-alpha therapy in children with HBeAg-positive immune-active chronic hepatitis B.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13598.
    PubMed     Abstract available


  34. LEE HW, Cho YY, Lee H, Lee JS, et al
    Effect of tenofovir alafenamide versus tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13601.
    PubMed     Abstract available


  35. CHEN Y, Zhao YL, Hao ZY, Zhang XJ, et al
    Long-term persistence of anti-HAV antibody conferred by a single dose of live-attenuated hepatitis A vaccine: results from 17-year follow-up.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13602.
    PubMed     Abstract available


  36. WONG RJ, Cheung R, Gish RG, Chitnis AS, et al
    Prevalence of Hepatitis E Infection among Adults with Concurrent Chronic Liver Disease.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13597.
    PubMed     Abstract available


  37. CHEN B, Huang H, Pan CQ
    The Role of Gut Microbiota in Hepatitis B Disease Progression and Treatment.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13595.
    PubMed     Abstract available


  38. PALMER AY, Chan K, Gold J, Layton C, et al
    A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
    PubMed     Abstract available


  39. CHANG JW, Lee JS, Lee HW, Kim BK, et al
    No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B.
    J Viral Hepat. 2021 Aug 12. doi: 10.1111/jvh.13594.
    PubMed     Abstract available


  40. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
    Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
    J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
    PubMed     Abstract available


  41. FREELAND C, Racho R, Kamischke M, Moraras K, et al
    Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment.
    J Viral Hepat. 2021 Aug 7. doi: 10.1111/jvh.13592.
    PubMed     Abstract available


  42. LEE WM, King WC, Janssen HLA, Ghany MG, et al
    Hepatitis B e Antigen Loss in Adults and Children with Chronic Hepatitis B Living in North America: A Prospective Cohort Study.
    J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13591.
    PubMed     Abstract available


  43. PERIERES L, Protopopescu C, Lo G, Marcellin F, et al
    Sibling status, home birth, tattoos and stitches are risk factors for chronic hepatitis B virus infection in Senegalese children: a cross-sectional survey.
    J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13589.
    PubMed     Abstract available


  44. DJEBALI-TRABELSI A, Marot A, Andre C, Deltenre P, et al
    Large-scale screening is not useful for identifying individuals with hepatitis B or C virus infection: a prospective Swiss study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13588.
    PubMed     Abstract available


  45. XU C, Bao Y, Zuo J, Li Y, et al
    Maternal chronic hepatitis B virus infection and the risk of preterm birth: a retrospective cohort analysis in Chinese Women.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13585.
    PubMed     Abstract available


  46. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
    Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
    PubMed     Abstract available


  47. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
    The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
    PubMed     Abstract available


    July 2021
  48. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
    Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
    J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
    PubMed     Abstract available


  49. WANG Y, Zhao Z, Zhang H, Lin Q, et al
    Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
    PubMed     Abstract available


  50. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
    Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
    PubMed     Abstract available


  51. OHKI T, Satov K, Kondo M, Goto E, et al
    Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
    PubMed     Abstract available


  52. ZHANG S, Chen Z, Wei J, Chi X, et al
    A model based on clinico-biochemical characteristics and deep learning features from MR images for assessing necroinflammatory activity in chronic hepatitis B.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13578.
    PubMed     Abstract available


  53. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
    Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
    PubMed     Abstract available


  54. HEYWOOD A, Dyda A, Hu W, Saha A, et al
    Seroprevalence of hepatitis B antibodies among international and domestic university students.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13580.
    PubMed     Abstract available


  55. KAMAL H, Fornes R, Simin J, Stal P, et al
    Risk of Hepatocellular Carcinoma in Hepatitis B and D Virus Co-Infected Patients: A Systematic Review and Meta-analysis of Longitudinal studies.
    J Viral Hepat. 2021 Jul 22. doi: 10.1111/jvh.13577.
    PubMed     Abstract available


  56. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
    Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
    J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
    PubMed     Abstract available


  57. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
    The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
    J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
    PubMed     Abstract available


  58. NA JE, Sinn DH, Lee JH, Jang HJ, et al
    Efficacy of entecavir vs tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
    J Viral Hepat. 2021 Jul 12. doi: 10.1111/jvh.13572.
    PubMed     Abstract available


  59. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
    A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
    PubMed     Abstract available


  60. LI J, Qu L, Sun X, Liu Y, et al
    Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg positive chronic hepatitis B naive patients.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13571.
    PubMed     Abstract available


  61. ERICE A, Varillas-Delgado D, Caballero C
    Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
    PubMed     Abstract available


  62. KAMALAPIRAT T, Ungtrakul T
    Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B".
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13566.
    PubMed     Abstract available


  63. LOU T, Li B, Xiong P, Jin C, et al
    External Validation of Hepatocellular Carcinoma Risk Scores in Patients with Chronic Hepatitis B Virus Infection in China.
    J Viral Hepat. 2021 Jul 4. doi: 10.1111/jvh.13569.
    PubMed     Abstract available


  64. FARSIMADAN M, Riahi SM, Muhammad HM, Emamvirdizadeh A, et al
    The Effects of Hepatitis B Virus Infection on Natural and IVF Pregnancy: A Meta-analysis Study.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13565.
    PubMed     Abstract available


  65. LIU Y
    Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13568.
    PubMed     Abstract available


  66. LIU Y
    Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B" - a reply.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13567.
    PubMed     Abstract available


  67. MCGUIRE FH, Andre K, Bradsher ML, Harrison D, et al
    Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
    J Viral Hepat. 2021;28:982-993.
    PubMed     Abstract available


    June 2021
  68. GIRALDEZ-GALLEGO A, Rodriguez-Seguel E, Pascasio-Acevedo JM
    Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13563.
    PubMed     Abstract available


  69. KIM HP, Edwards A, Reeve BB, Golin CE, et al
    Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
    PubMed     Abstract available


  70. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
    PubMed     Abstract available


  71. YOO S, Lim TS, Lee HW, Kim JK, et al
    Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13560.
    PubMed     Abstract available


  72. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    PubMed     Abstract available


  73. NISHIDA Y, Imamura M, Yuji T, Morio K, et al
    Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13557.
    PubMed     Abstract available


  74. DONG Y, Li A, Zhu S, Chen W, et al
    Biopsy-proven liver cirrhosis in young children: A 10-year cohort study.
    J Viral Hepat. 2021;28:959-963.
    PubMed     Abstract available


  75. CHENG D, Han B, Zhang W, Wu W, et al
    Clinical effects of NTCP-inhibitor myrcludex B.
    J Viral Hepat. 2021;28:852-858.
    PubMed     Abstract available


    May 2021
  76. WANG S, Fang S, Liu Y
    The 5-year cumulative incidence HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    J Viral Hepat. 2021 May 29. doi: 10.1111/jvh.13553.
    PubMed     Abstract available


  77. BROWN C, Siegele M, Wright M, Cook C, et al
    Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
    PubMed     Abstract available


  78. RODRIGUEZ-TAJES S, Lens S, Forns X
    Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13555.
    PubMed     Abstract available


  79. ARSLAN F, Franci G, Nastri BM, Pagliano P, et al
    Hepatitis B virus-induced Hepatocarcinogenesis: A Virological and Oncological Perspective.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13551.
    PubMed     Abstract available


  80. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
    Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
    PubMed     Abstract available


  81. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
    Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
    PubMed     Abstract available


  82. DUFFELL E, Cortez-Pinto H, Simonova M, Dalgard O, et al
    Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13545.
    PubMed     Abstract available


  83. LIU PC, Chan C, Huang YH, Chen YJ, et al
    Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
    PubMed     Abstract available


  84. KIM S, Powell J, Naugle J, Ricco M, et al
    Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
    PubMed     Abstract available


  85. NANA J, Skaare K, Bosson JL, Leroy V, et al
    EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with Hepatitis B: an independent validation.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13548.
    PubMed     Abstract available


  86. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
    Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
    PubMed     Abstract available


  87. COMBET C, Bhardwaj N, Hedskog C, Podlaha O, et al
    Hepatitis B Virus Genome Diversity in Adolescents: Tenofovir Disoproxil Fumarate Treatment Effect and HBeAg Seroconversion.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13547.
    PubMed     Abstract available


  88. HUANG PY, Wang JH, Hung CH, Lu SN, et al
    The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13528.
    PubMed     Abstract available


  89. WOLF JM, Pereira VRZB, Simon D, Lunge VR, et al
    Temporal and geographic spreading of hepatitis B virus genotype A (HBV-A) in Brazil and the Americas.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13527.
    PubMed     Abstract available


  90. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
    Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
    PubMed     Abstract available


  91. LEE J, Kim GA, Kim HJ, Cho S, et al
    Tenofovir Disoproxil Fumarate on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Failure to Preceding Treatments: A Nationwide Cohort Study.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13530.
    PubMed     Abstract available


    April 2021
  92. KUMADA T
    Reply to: 'Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis'.
    J Viral Hepat. 2021 Apr 28. doi: 10.1111/jvh.13514.
    PubMed    


  93. CHEN H, Ding X, Liao G, Xia M, et al
    Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
    J Viral Hepat. 2021 Apr 26. doi: 10.1111/jvh.13526.
    PubMed     Abstract available


  94. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
    Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
    PubMed     Abstract available


  95. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
    Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
    PubMed     Abstract available


  96. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
    Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
    PubMed     Abstract available


  97. YU W, Ji H, Long F, Chen S, et al
    Inhibition of Hepatitis E Virus Replication by Zinc-Finger Antiviral Protein synergizes with IFN-beta.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13522.
    PubMed     Abstract available


  98. ANUGWOM C, Campbell C, Debes JD
    Assessment of subclinical effects of Hepatitis E virus infection in the United States.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13519.
    PubMed     Abstract available


  99. COOPER SL, King WC, Mogul DB, Ghany MG, et al
    Clinical Significance of Quantitative e Antigen in a Cohort of Hepatitis B Virus Infected Children and Adults in North America.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13520.
    PubMed     Abstract available


  100. MOKAYA J, Vasylyeva TI, Barnes E, Ansari MA, et al
    Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13525.
    PubMed     Abstract available


  101. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
    Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
    PubMed     Abstract available


  102. KAMALAPIRAT T, Yingcharoen K, Ungtrakul T, Soonklang K, et al
    Assessing Risk Scores for Predicting Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13517.
    PubMed     Abstract available


  103. SHEN DT, Han PC, Ji DZ, Chen HY, et al
    Epidemiology estimates of hepatitis D in individuals co-infected with HIV and HBV, 2002-2018: a systematic review and meta-analysis.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13512.
    PubMed     Abstract available


  104. HARTARD C, Fenaux H, Gentilhomme A, Murray JM, et al
    Variability in molecular characteristics of Hepatitis E Virus quasispecies could modify viral surface properties and transmission.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13513.
    PubMed     Abstract available


  105. WENG F
    Comment on "Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis".
    J Viral Hepat. 2021 Apr 19. doi: 10.1111/jvh.13515.
    PubMed     Abstract available


  106. DZINGIRAI B, Katsidzira L, Matyanga CMJ, Postma MJ, et al
    Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.
    J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13510.
    PubMed     Abstract available


  107. YAO K, Liu J, Wang J, Yan X, et al
    Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the gray zone.
    J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13511.
    PubMed     Abstract available


  108. ZHANG Y, Xu W, Zhu X, Li X, et al
    The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
    J Viral Hepat. 2021;28:592-600.
    PubMed     Abstract available


  109. LEE TH, Chan A, Bryan W, Park L, et al
    Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    J Viral Hepat. 2021;28:630-636.
    PubMed     Abstract available


    March 2021
  110. RODRIGUEZ-TAJES S, Pocurull A, Lens S, Marino Z, et al
    Efficacy of an accelerated double dose Hepatitis B vaccine regimen in patients with cirrhosis.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13509.
    PubMed     Abstract available


  111. BUTT AA, Yan P
    Natural History of Hepatitis C Virus Infection in a Large National Seroconversion Cohort in the Direct Acting Antiviral Agent Era: Results from ERCHIVES.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13507.
    PubMed     Abstract available


  112. SAMALA N, Abdallah W, Poole A, Shamseddeen H, et al
    Insight Into The Acute hepatitis A Outbreak In Indiana.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13504.
    PubMed     Abstract available


  113. JI JH, Park SY, Son WJ, Shin HJ, et al
    External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13506.
    PubMed     Abstract available


  114. LIU CH, Sun HY, Hsieh SM, Liu WC, et al
    Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct acting antivirals and antiretroviral therapy.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13502.
    PubMed     Abstract available


  115. BAIANO CX, Caven M, Robinson EM, Dillon JF, et al
    Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13505.
    PubMed     Abstract available


  116. MACGREGOR L, Ward Z, Martin NK, Nicholls J, et al
    The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13503.
    PubMed     Abstract available


  117. POST G, Howell J, Sow A, Ndow G, et al
    Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B.
    J Viral Hepat. 2021 Mar 22. doi: 10.1111/jvh.13499.
    PubMed     Abstract available


  118. FARAG MS, Fung S, Tam E, Doucette K, et al
    Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
    J Viral Hepat. 2021 Mar 22. doi: 10.1111/jvh.13500.
    PubMed     Abstract available


  119. MACIAS J, Tellez F, de Los Santos I, Morano LE, et al
    Impact of recent drug use on the efficacy of Elbasvir/Grazoprevir for HCV-infected people on opioid agonist therapy.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13496.
    PubMed     Abstract available


  120. JIANG JJ, Shiels MS, O'Brien TR
    Death Certificates Compared to SEER-Medicare Data for Surveillance of Liver Cancer Mortality Due to Hepatitis B or Hepatitis C Infection.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13498.
    PubMed     Abstract available


  121. DOLMAN GE, Koffas A, Phipps E, Kennedy PTF, et al
    Clinical and occupational health management of healthcare workers living with chronic hepatitis B: UK policy and international comparisons.
    J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13494.
    PubMed     Abstract available


  122. XIAO Y, Wallace J, Thompson A, Hellard M, et al
    A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia.
    J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13495.
    PubMed     Abstract available


  123. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
    Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
    J Viral Hepat. 2021;28:548-557.
    PubMed     Abstract available


    February 2021
  124. BAR N, Levy S, Deutsch L, Leshno M, et al
    Hepatitis C related cognitive impairment: impact of viral and host factors and response to therapy.
    J Viral Hepat. 2021 Feb 23. doi: 10.1111/jvh.13492.
    PubMed     Abstract available


  125. BANDERA A, Lorenzini P, Taramasso L, Cozzi-Lepri A, et al
    The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: data from the ICONA Foundation Cohort.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13488.
    PubMed     Abstract available


  126. VEGAS JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M, et al
    Reduction in hepatitis C-related hospitalisations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13491.
    PubMed     Abstract available


  127. SHIMAKAWA Y, Vernoux L, Gabassi A, Mercier-Delarue S, et al
    Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS).
    J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13489.
    PubMed     Abstract available


  128. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
    J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487.
    PubMed     Abstract available


  129. TOKUCHI Y, Suda G, Kimura M, Maehara O, et al
    Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13484.
    PubMed     Abstract available


  130. FRAZZONI L, Sikandar U, Mazzella G, Fuccio L, et al
    A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13486.
    PubMed     Abstract available


  131. GUZELBULUT F, Gokcen P, Can G, Adali G, et al
    Validation of the HCC-RESCUE Score to Predict Hepatocellular Carcinoma Risk in Caucasian Chronic Hepatitis B Patients Under Entecavir or Tenofovir Therapy.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13485.
    PubMed     Abstract available


  132. SAHAKYAN Y, Lee-Kim V, Bremner KE, Bielecki JM, et al
    Impact of direct acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: systematic review and meta-analysis.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13482.
    PubMed     Abstract available


  133. VERGARA M, Miquel M, Vela E, Cleries M, et al
    Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13479.
    PubMed     Abstract available


  134. TUNG CH, Li CY, Chen YC, Chen YC, et al
    Association between nucleos(t)ide analogue therapy for hepatitis B and Sjogren's syndrome: 15-year analysis of the national database of Taiwan.
    J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13481.
    PubMed     Abstract available


  135. KREKULOVA L, Honzak R, Riley LW
    Viral hepatitis C pandemic: challenges and threats to its elimination.
    J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13480.
    PubMed     Abstract available


  136. WEI YJ, Hsu PY, Lee JJ, Niu SW, et al
    Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uremic patients receiving hemodialysis in Taiwan- the FORMOSA-LIKE group.
    J Viral Hepat. 2021 Feb 3. doi: 10.1111/jvh.13477.
    PubMed     Abstract available


  137. PRITCHARD H, Hwang JP, Angelidakis G, Yibirin M, et al
    Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection.
    J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478.
    PubMed     Abstract available


    January 2021
  138. KIRINO S, Tamaki N, Kurosaki M, Inada K, et al
    Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    J Viral Hepat. 2021 Jan 23. doi: 10.1111/jvh.13473.
    PubMed     Abstract available


  139. WANG SQ, Shen Y, Li J, Liu Y, et al
    Entecavir-induced Interferon-lambda1 suppresses type 2 innate lymphoid Cells in Patients with Hepatitis B virus-related liver cirrhosis.
    J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13476.
    PubMed     Abstract available


  140. LOCKART I, Hajarizadeh B, Alavi M, Davison S, et al
    Title: Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
    J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13475.
    PubMed     Abstract available


  141. WILDER JM, Evon DM, Jean Proeschold-Bell R, Yao J, et al
    Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives.
    J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474.
    PubMed     Abstract available


  142. SONG A, Xiaoxiao W, Lu J, Jin Y, et al
    Durability of Hepatitis B Surface Antigen seroclearance and subsequent Risk for hepatocellular Carcinoma : a meta-analysis.
    J Viral Hepat. 2021 Jan 17. doi: 10.1111/jvh.13471.
    PubMed     Abstract available


  143. XIONG Y, Liu C, Huang S, Wang J, et al
    Impact of maternal infection with hepatitis B virus on pregnancy complications and neonatal outcomes for women undergoing assisted reproductive technology treatment: a population-based study.
    J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13472.
    PubMed     Abstract available


  144. SU X, Zhao X, Deng JL, Li SN, et al
    Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
    J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13469.
    PubMed     Abstract available


  145. CHEN B, Ma ZH, Xu B, Chang H, et al
    Evaluation of seven Rapid Diagnostic Tests for Detection of Hepatitis C Virus Antibodies in China.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13466.
    PubMed     Abstract available


  146. SHUMBUSHO F, Liu AF, Kateera F, Kabahizi J, et al
    Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13467.
    PubMed     Abstract available


  147. FRANCESCA ROMANA P, Francesco S, Massimo S, Antonio Giulio B, et al
    Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care center: results of the Telepass project.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13465.
    PubMed     Abstract available


    December 2020
  148. MOHAREB AM, Kouame GM, Gabassi A, Gabillard D, et al
    Mortality in relation to hepatitis B virus (hbv) infection status among hiv-hbv co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy.
    J Viral Hepat. 2020 Dec 31. doi: 10.1111/jvh.13461.
    PubMed     Abstract available


  149. KUSHNER T, Kaplowitz E, Mei R, Xu C, et al
    Adherence to pregnancy hepatitis B care guidelines in women and infants in the and evaluation of two interventions to improve care: a multi-center hospital-based study.
    J Viral Hepat. 2020 Dec 29. doi: 10.1111/jvh.13459.
    PubMed     Abstract available


  150. O'GORMAN P, Strahan O, Ferguson D, Monaghan A, et al
    Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C.
    J Viral Hepat. 2020 Dec 28. doi: 10.1111/jvh.13460.
    PubMed     Abstract available


  151. KUMADA T, Toyoda H, Yasuda S, Miyake N, et al
    Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13457.
    PubMed     Abstract available


  152. COOPER C, Driedger M, Wong D, Haylock-Jacobs S, et al
    Distinct Hepatitis B and HIV co-infected populations in Canada.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13453.
    PubMed     Abstract available


  153. FABBIANI M, Lombardi A, Colaneri M, Del Poggio P, et al
    High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13454.
    PubMed     Abstract available


  154. WASUWANICH P, Ingviya T, Thawillarp S, Teshale EH, et al
    Hepatitis E-Associated Hospitalizations in the United States: 2010-2015 and 2015-2017.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13458.
    PubMed     Abstract available


  155. YOUNOSSI ZM, Stepanova M, Younossi I, Racila A, et al
    Development and validation of a hepatitis B-specific health-related quality of life instrument: CLDQ-HBV.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13451.
    PubMed     Abstract available


  156. CHANG JW, Kim SU
    Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13450.
    PubMed     Abstract available


  157. CAMPBELL C, Wang T, McNaughton AL, Barnes E, et al
    Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis.
    J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13452.
    PubMed     Abstract available


  158. GORRIS M, van der Lecq BM, van Erpecum KJ, de Bruijne J, et al
    Treatment for Chronic Hepatitis E Virus Infection: A Systematic Review and Meta-analysis.
    J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13456.
    PubMed     Abstract available


  159. PENG CW, Jeng WJ, Chien RN, Liaw YF, et al
    The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B.
    J Viral Hepat. 2020 Dec 3. doi: 10.1111/jvh.13449.
    PubMed     Abstract available


  160. LIU Y, Mo Y, Wu A
    Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    J Viral Hepat. 2020 Dec 2. doi: 10.1111/jvh.13448.
    PubMed     Abstract available


  161. PAPATHEODORIDI A, Chatzigeorgiou A, Chrysavgis L, Lembessis P, et al
    Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients.
    J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13446.
    PubMed     Abstract available


  162. CHAN K, Elsum I, Gold J, Layton C, et al
    Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
    J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13447.
    PubMed     Abstract available


  163. CHEN L, Huang S, Yang J, Cheng X, et al
    Clinical characteristics in patients with SARS-CoV-2/HBV co-infection.
    J Viral Hepat. 2020;27:1504-1507.
    PubMed     Abstract available


    November 2020
  164. TADA T, Toyoda H, Kumada T, Kurisu A, et al
    Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13444.
    PubMed     Abstract available


  165. WHITELEY D, Speakman E, Elliott L, Davidson K, et al
    Provider-related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13443.
    PubMed     Abstract available


  166. RAZAVI H
    The cost effectiveness of hepatitis C virus elimination in low and middle-income countries.
    J Viral Hepat. 2020 Nov 17. doi: 10.1111/jvh.13442.
    PubMed     Abstract available


  167. YUJI T, Imamura M, Uchida T, Ohya K, et al
    Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection - Pilot study.
    J Viral Hepat. 2020 Nov 16. doi: 10.1111/jvh.13441.
    PubMed     Abstract available


  168. ANASTASIOU OE, Yurdaydin C, Maasoumy B, Hardtke S, et al
    A transient early HBV DNA increase during PEG-IFNalpha therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction.
    J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13439.
    PubMed     Abstract available


  169. WEINHEIMER-HAUS EM, Yu X, Singal AG, Naylor KB, et al
    Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan.
    J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13438.
    PubMed     Abstract available


  170. KIM D, Alshuwaykh OS, Cholankeril G, Wong RJ, et al
    Trends in Mortality in Hepatitis C Infection and Alcoholic Liver Disease based on Drug Overdose in the United States.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13435.
    PubMed     Abstract available


  171. RIDRUEJO E, Pinero F, Mendizabal M, Silva M, et al
    Direct-Acting Antivirals Treatment Failure in Genotype 2 Hepatitis C chronic Infection.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13433.
    PubMed     Abstract available


  172. KAPADIA SN, Katzman C, Fong C, Eckhardt BJ, et al
    Hepatitis C Testing and Treatment Uptake among Young People who Use Opioids in New York City: A Cross-Sectional Study.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13437.
    PubMed     Abstract available


  173. WU D, Hu S, Chen G, Jiao C, et al
    Association of Hepatitis C Infection and Risk of Kidney Cancer: A Systematic Review and Meta-analysis of Observational Studies.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13434.
    PubMed     Abstract available


  174. SHEU MJ, Liang FW, Lu TH
    Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13436.
    PubMed     Abstract available


  175. MULDER MB, de Man RA, Kamar N, Durmaz G, et al
    Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis e virus infection.
    J Viral Hepat. 2020 Nov 1. doi: 10.1111/jvh.13432.
    PubMed     Abstract available


    October 2020
  176. GALLACHER J, McPherson S
    Progress towards micro-elimination of hepatitis C in the custodial setting.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13428.
    PubMed    


  177. FAHNOE U, Pedersen MS, Solund C, Ernst A, et al
    Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13430.
    PubMed     Abstract available


  178. GOYAL A, Perelson AS, Kandathil AJ, Quinn J, et al
    HIV influences clustering and intracellular replication of hepatitis C virus.
    J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13429.
    PubMed     Abstract available


  179. WOLF JM, De Carli S, Pereira VRZB, Simon D, et al
    Temporal evolution and global spread of hepatitis B virus genotype G.
    J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13431.
    PubMed     Abstract available


  180. IBRAHIM ES, Abdel-Samiee M, Youssef MI, El-Shazly H, et al
    Variceal Recurrence 4 Years post Endoscopic Band Ligation in Hepatitis C Patients who Achieved Sustained Virological Response with Oral Direct Acting Antiviral Therapy.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13426.
    PubMed     Abstract available


  181. REYES-URUENA J, Celly A, Moreno S, Majo X, et al
    Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13427.
    PubMed     Abstract available


  182. ANKCORN M, Said B, Morgan D, Elsharkawy AM, et al
    Persistent Hepatitis E virus infection across England and Wales 2009-2017: Demography, virology and outcomes.
    J Viral Hepat. 2020 Oct 18. doi: 10.1111/jvh.13424.
    PubMed     Abstract available


  183. CHAN J, Kim JJ, Barrett BK, Hamadeh A, et al
    Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis.
    J Viral Hepat. 2020 Oct 16. doi: 10.1111/jvh.13419.
    PubMed     Abstract available


  184. LAURSEN TL, Villesen IF, Leeming DJ, Karsdal MA, et al
    Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
    J Viral Hepat. 2020 Oct 15. doi: 10.1111/jvh.13416.
    PubMed     Abstract available


  185. MAFIRAKUREVA N, Lim AG, Khalid GG, Aslam K, et al
    Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    J Viral Hepat. 2020 Oct 14. doi: 10.1111/jvh.13422.
    PubMed     Abstract available


  186. LEE J, Cho S, Kim HJ, Lee H, et al
    High Level of Medication Adherence Is Required to Lower Mortality in Patients with Chronic Hepatitis B Taking Entecavir: A Nationwide Cohort Study.
    J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13418.
    PubMed     Abstract available


  187. RAFIQUE S, Zahid S, Ali A, Tariq M, et al
    Genome wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications.
    J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13417.
    PubMed     Abstract available


  188. CHOTIYAPUTTA W, Poosanasuwansri K, Kiattisunthorn K, Chainuvati S, et al
    Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction.
    J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13420.
    PubMed     Abstract available


  189. POOLA S, Sanaka S, Sewell K, Tillmann HL, et al
    Hepatitis B Surface Antibody Titers and Hepatitis B Reactivation with Direct-Acting Antiviral Therapy for Hepatitis C.
    J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13421.
    PubMed     Abstract available


  190. CHANG JW, Lee JS, Lee HW, Kim BK, et al
    Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
    J Viral Hepat. 2020 Oct 7. doi: 10.1111/jvh.13411.
    PubMed     Abstract available


    September 2020
  191. KOC OM, Kuypers D, Dupont LJ, Vos R, et al
    The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates.
    J Viral Hepat. 2020 Sep 28. doi: 10.1111/jvh.13414.
    PubMed     Abstract available


  192. RAZAVI H, Blach S, Razavi-Shearer D
    The case for simplifying and using absolute targets for viral hepatitis elimination goals.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13412.
    PubMed     Abstract available


  193. MARTINEZ SANZ J, Vivancos MJ, Sanchez-Conde M, Gomez-Ayerbe C, et al
    Hepatitis C and HIV combined screening in primary care: a cluster randomized trial.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13413.
    PubMed     Abstract available


  194. JOHNSON PJ, Berhane S, Walker AJ, Gordon FH, et al
    Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408.
    PubMed     Abstract available


  195. RODRIGUEZ-TAJES S, Miralpeix A, Costa J, Lopez-Sune E, et al
    Low risk of hepatitis b reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
    J Viral Hepat. 2020 Sep 24. doi: 10.1111/jvh.13410.
    PubMed     Abstract available


  196. ZHANG Y, Jiang X, Zhao Y, Xu Y, et al
    Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A Meta-analysis.
    J Viral Hepat. 2020 Sep 22. doi: 10.1111/jvh.13409.
    PubMed     Abstract available


  197. THAUNG YM, Simion Chasela C C, Chew KW, Minior T, et al
    Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus co-infected patients in Myanmar.
    J Viral Hepat. 2020 Sep 16. doi: 10.1111/jvh.13405.
    PubMed     Abstract available


  198. WU J, Yu J, Shi X, Li W, et al
    Epidemiological and Clinical Characteristics of 70 Cases of Coronavirus Disease and Concomitant Hepatitis B Virus Infection: A Multicenter Descriptive Study.
    J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13404.
    PubMed     Abstract available


  199. CHEN JY, Cheng PN, Chiu YC, Chiu HC, et al
    Persistent Augmentation of Central Arterial Stiffness Following Viral Clearance by Direct Acting Antivirals in Chronic Hepatitis C.
    J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13406.
    PubMed     Abstract available


  200. BEEBEEJAUN K, Amin Z, Letley L, Kara E, et al
    Impact of a nurse-led enhanced monitoring, management and contact tracing intervention for chronic hepatitis B in England, 2015-2017.
    J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13403.
    PubMed     Abstract available


  201. LIEM KS, Wong DK, Fung S, Zahirieh A, et al
    Maintained virologic suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients.
    J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13401.
    PubMed     Abstract available


  202. LINDGREN P, Lofvendahl S, Bradvik G, Weiland O, et al
    Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals.
    J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13398.
    PubMed     Abstract available


  203. VAN DIJK M, Drenth JPH
    Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
    J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13399.
    PubMed     Abstract available


  204. WUNGU CDK, Ariyanto FC, Prabowo GI, Soetjipto, et al
    Meta-analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma risk.
    J Viral Hepat. 2020 Sep 7. doi: 10.1111/jvh.13402.
    PubMed     Abstract available


  205. LIU Y, Chang S, Martin R, Flaherty J, et al
    Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance.
    J Viral Hepat. 2020 Sep 7. doi: 10.1111/jvh.13397.
    PubMed     Abstract available


  206. CON D, Goodwin T, Majeed A, Roberts S, et al
    Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis.
    J Viral Hepat. 2020 Sep 7. doi: 10.1111/jvh.13400.
    PubMed     Abstract available


  207. MIZOKAMI M, Liu LJ, Fujiyama N, Littman M, et al
    Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13395.
    PubMed     Abstract available


  208. BEUDEKER BJB, Groothuismink ZMA, de Man RA, Witjes CDM, et al
    Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV associated early stage hepatocellular carcinoma: results from a Dutch long-term follow-up study.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13394.
    PubMed     Abstract available


  209. PRINCE DS, Pipicella JL, Fraser M, Alvaro F, et al
    Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or "re-diagnose" infections is effective in Australia.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393.
    PubMed     Abstract available


  210. PALLERLA SR, Schembecker S, Meyer CG, Linh LTK, et al
    Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13396.
    PubMed     Abstract available


    August 2020
  211. WADE AJ, Doyle JS, Draper B, Howell J, et al
    In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
    J Viral Hepat. 2020 Aug 29. doi: 10.1111/jvh.13391.
    PubMed     Abstract available


  212. VAN NUIL JI, Umutesi G, Shumbusho F, Kateera F, et al
    Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).
    J Viral Hepat. 2020 Aug 28. doi: 10.1111/jvh.13386.
    PubMed     Abstract available


  213. SYED TA, Cherian R, Lewis S, Sterling RK, et al
    Telemedicine HCV Treatment in Department of Corrections Results in High SVR In Era of Direct-Acting Antivirals.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13392.
    PubMed     Abstract available


  214. ARNONE OC, Serranti D, Bartolini E, Mastrangelo G, et al
    Chronic Hepatitis B in Children, Report of a Single-Centre Longitudinal Study on 152 Children.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13382.
    PubMed     Abstract available


  215. LI S, Li M, He Q, Liang Z, et al
    Characterization of hepatitis E virus natural infection in farmed rabbits.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13387.
    PubMed     Abstract available


  216. TAO YC, Chen EQ
    Rely to: "Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues".
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13390.
    PubMed     Abstract available


  217. KIM SU, Chon YE, Seo YS, Lee HW, et al
    A multi-center study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13384.
    PubMed     Abstract available


  218. PFLUGER LS, Schulze Zur Wiesch J, Polywka S, Lutgehetmann M, et al
    Hepatitis delta virus propagation enabled by hepatitis C virus - scientifically intriguing; but is it relevant to clinical practice?
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13385.
    PubMed     Abstract available


  219. CHEN J, Wang Y, Wu J
    Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13383.
    PubMed     Abstract available


  220. PHILLIPS C, O'Sullivan, Schulkind J, Jones CJ, et al
    Authors' reply to letter: In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care'.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13389.
    PubMed     Abstract available


  221. SUNG JC, Wyatt B, Perumalswami PV, Branch A, et al
    Response to "Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center".
    J Viral Hepat. 2020 Aug 25. doi: 10.1111/jvh.13381.
    PubMed     Abstract available


  222. GIULIANI R, Casigliani V, Fornili M, Sebastiani T, et al
    HCV micro-elimination in two prisons in Milan, Italy: a model of care.
    J Viral Hepat. 2020 Aug 20. doi: 10.1111/jvh.13376.
    PubMed     Abstract available


  223. MENDIZABAL M, Testa P, Rojas M, Colaci CS, et al
    Pilot study using the ECHO model to enhance linkage to care for patients with hepatitis C in the custodial setting.
    J Viral Hepat. 2020 Aug 19. doi: 10.1111/jvh.13374.
    PubMed     Abstract available


  224. MORA M, Goodyear T, Marcellin F, Shoveller J, et al
    Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13378.
    PubMed     Abstract available


  225. DONG Y, Li M, Zhu S, Gao X, et al
    De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected pediatric patients with advanced fibrosis.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13372.
    PubMed     Abstract available


  226. HAMADEH A, Haines A, Feng Z, Thein HH, et al
    Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada using population-based cohort studies.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13373.
    PubMed     Abstract available


  227. RAHAL H, Boutros S, Farhat M, Kullar R, et al
    Estimating Pediatric Hepatitis C Prevalence in the United States.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13377.
    PubMed     Abstract available


  228. MEDRZYCKI M, Kamili S, Purdy MA
    Hepatitis A Virus Survival on Drug Paraphernalia.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13379.
    PubMed     Abstract available


  229. BARRE T, Nishimwe ML, Protopopescu C, Marcellin F, et al
    Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13380.
    PubMed     Abstract available


  230. MESSINA V, Russo A, Parente E, Russo G, et al
    Innovative procedures for micro-elimination of hcv infection in persons who use drugs.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13375.
    PubMed     Abstract available


  231. ZENG W, Liu M, Peng S, Yu G, et al
    Is the life-long entecavir treatment really inevitable in chronic hepatitis B patients?
    J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13369.
    PubMed     Abstract available


  232. HUANG Y, Li X, Zheng X, Tian X, et al
    Bayesian Network to Predict Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients.
    J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13368.
    PubMed     Abstract available


  233. LIU Z, Shi O, Zhang T, Jin L, et al
    Disease burden of viral hepatitis A, B, C, and E: a systematic analysis.
    J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13371.
    PubMed     Abstract available


  234. PERPINAN E, Perez-Del-Pulgar S, Londono MC, Marino Z, et al
    Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8(+) T cells after direct-acting antiviral therapies.
    J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13370.
    PubMed     Abstract available


    July 2020
  235. WRANKE A, Hardtke S, Heidrich B, Dalekos G, et al
    Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
    J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13366.
    PubMed     Abstract available


  236. CASTRO FILHO E, Piedade J, Castro R, Luz PM, et al
    Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: a systematic review and meta-analysis.
    J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13364.
    PubMed     Abstract available


  237. YIM HJ, Suh SJ, Jung YK, Hwang SG, et al
    Tenofovir-based combination therapy or monotherapy for multi-drug resistant chronic hepatitis B: Long-term data from a multicenter cohort study.
    J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13363.
    PubMed     Abstract available


  238. FREELAND C, Vader D, Cohen C, George B, et al
    A Predictive Model for Hepatitis B Infection Among High-Risk Adults Using a Community-Based Sample in Greater Philadelphia.
    J Viral Hepat. 2020 Jul 23. doi: 10.1111/jvh.13365.
    PubMed     Abstract available


  239. IRVIN R, Ntiri-Reid B, Kleinman M, Agee T, et al
    Sharing the Cure: Building Primary Care and Public Health Infrastructure to Improve the Hepatitis C Care Continuum in Maryland.
    J Viral Hepat. 2020 Jul 15. doi: 10.1111/jvh.13360.
    PubMed     Abstract available


  240. WONG SW, Chan WK, Mohamed R
    Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B.
    J Viral Hepat. 2020 Jul 15. doi: 10.1111/jvh.13361.
    PubMed     Abstract available


  241. DAI CY, Huang JF, Chuang WL, Yu ML, et al
    Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: some issues.
    J Viral Hepat. 2020 Jul 5. doi: 10.1111/jvh.13358.
    PubMed     Abstract available


  242. DIMOVA RB, Rude E, Talal AH
    Age and Risk-Factor Based Serologic Screening for Hepatitis C Virus among an Urban, High-Risk Population.
    J Viral Hepat. 2020 Jul 2. doi: 10.1111/jvh.13359.
    PubMed     Abstract available


    June 2020
  243. NANGIA G, Vierling JM, Kwo P, Brown DD, et al
    Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials.
    J Viral Hepat. 2020 Jun 28. doi: 10.1111/jvh.13357.
    PubMed     Abstract available


  244. DALBENI A, Romano S, Bevilacqua M, Piccoli A, et al
    Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with low-moderate liver fibrosis.
    J Viral Hepat. 2020 Jun 27. doi: 10.1111/jvh.13355.
    PubMed     Abstract available


  245. RINGLANDER J, Skoglund C, Prakash K, Andersson ME, et al
    Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA.
    J Viral Hepat. 2020 Jun 27. doi: 10.1111/jvh.13356.
    PubMed     Abstract available


  246. CHEN YC, Thio CL, Kamangar F, Cox AL, et al
    Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.
    J Viral Hepat. 2020 Jun 24. doi: 10.1111/jvh.13354.
    PubMed     Abstract available


  247. VERBINNEN T, Hodari M, Talloen W, Berke JM, et al
    Virology analysis of chronic hepatitis B infected patients treated for 28 days with JNJ-56136379 monotherapy.
    J Viral Hepat. 2020 Jun 24. doi: 10.1111/jvh.13351.
    PubMed     Abstract available


  248. ABE H, Ushijima Y, Bikangui R, Ondo GN, et al
    First evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa.
    J Viral Hepat. 2020 Jun 21. doi: 10.1111/jvh.13348.
    PubMed     Abstract available


  249. YOUSIF MM, Ahmed H, Elsadek HM, Shendi AM, et al
    Real-World Safety and Effectiveness Of Retreatment Of Egyptian Chronic Hepatitis C Patients Not Responding to NS5A Inhibitor-Based Therapies.
    J Viral Hepat. 2020 Jun 21. doi: 10.1111/jvh.13349.
    PubMed     Abstract available


  250. ZHANG H, Yan X, Yang C, Zhan Q, et al
    Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen-activated hepatic stellate cells exacerbate the progression of chronic hepatitis B virus infection.
    J Viral Hepat. 2020 Jun 19. doi: 10.1111/jvh.13352.
    PubMed     Abstract available


  251. CUADRADO A, Perello C, Cabezas J, Llerena S, et al
    Update on epidemiology of hepatitis B in a low-endemic European country: there is still much to do.
    J Viral Hepat. 2020 Jun 19. doi: 10.1111/jvh.13350.
    PubMed     Abstract available


  252. HWA YOUNG C, Mai Thi H, Kim KA, Cho H, et al
    Association between viral hepatitis infection and Parkinson's disease: A population-based prospective study.
    J Viral Hepat. 2020 Jun 17. doi: 10.1111/jvh.13346.
    PubMed     Abstract available


  253. OTHMAN B, Al-Najjar MAA, Othman D, Al-Qudah R, et al
    Prevalence, knowledge of and attitude towards Hepatitis B virus among pregnant females in Jordan.
    J Viral Hepat. 2020 Jun 7. doi: 10.1111/jvh.13342.
    PubMed     Abstract available


  254. WU J, Huang F, Ling Z, Liu S, et al
    Altered fecal microbiota on the expression of Th Cells responses in the exacerbation of patients with hepatitis E infection.
    J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13344.
    PubMed     Abstract available


  255. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    Determinants of Stigma among Patients with Hepatitis C Virus (HCV) Infection.
    J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13343.
    PubMed     Abstract available


  256. CHON YE, Jung KS, Ha Y, Kim MN, et al
    High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis.
    J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13345.
    PubMed     Abstract available


  257. MINA M, Underwood A, Eltahla A, Wu BR, et al
    Anti-Envelope antibody responses in highly-exposed seronegative individuals may be associated with protection from HCV infection.
    J Viral Hepat. 2020 Jun 4. doi: 10.1111/jvh.13339.
    PubMed     Abstract available


  258. JACK K, Linsley P, JamesThomson B, Irving WL, et al
    How do people in prison feel about opt-out hepatitis C virus testing?
    J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13338.
    PubMed     Abstract available


  259. KAPLAN DE, Medvedeva E, Serper M
    Care Quality and Outcomes among U.S. Veterans with Chronic Hepatitis B in the Hepatitis C Direct Acting Antiviral Era.
    J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13340.
    PubMed     Abstract available


  260. POLLOCK KG, McDonald SA, Gunson R, McLeod A, et al
    Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype.
    J Viral Hepat. 2020 Jun 1. doi: 10.1111/jvh.13337.
    PubMed     Abstract available


    May 2020
  261. CONNOLEY D, Francis-Graham S, Storer M, Ekeke N, et al
    Detection, stratification, and treatment of hepatitis C positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
    J Viral Hepat. 2020 May 25. doi: 10.1111/jvh.13336.
    PubMed     Abstract available


  262. DE LEDINGHEN V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, et al
    Sofosbuvir-based regimens are suboptimal in patients with genotype 2 chronic hepatitis C infection: Real-life experience from the HEPATHER ANRS CO22 cohort.
    J Viral Hepat. 2020 May 21. doi: 10.1111/jvh.13321.
    PubMed     Abstract available


  263. DIETZ J, Kalinina OV, Vermehren J, Peiffer KH, et al
    Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322.
    PubMed     Abstract available


  264. YE W, Li X
    Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13323.
    PubMed     Abstract available


  265. KIM NG, Kullar R, Khalil H, Saab S, et al
    Meeting the WHO Hepatitis C Virus Elimination Goal: Review of Treatment in Pediatrics.
    J Viral Hepat. 2020 May 9. doi: 10.1111/jvh.13317.
    PubMed     Abstract available


  266. LI MR, Xu ZG, Lu JH, Zheng HW, et al
    Clinical Features of Hepatitis B Patients at Immune-tolerance Phase with Basal Core Promoter and/or Precore Mutations.
    J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13315.
    PubMed     Abstract available


  267. NING G, Zhen LM, Xu WX, Li XJ, et al
    Suppression of complement component2 expression by hepatitis B virus contributes to the viral persistence in chronic hepatitis B patients.
    J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13319.
    PubMed     Abstract available


  268. YUEN L, Revill PA, Rosenberg G, Wagner J, et al
    HBV variants are common in the "immune-tolerant"phase of chronic hepatitis B.
    J Viral Hepat. 2020 May 8. doi: 10.1111/jvh.13318.
    PubMed     Abstract available


  269. LIM TS, Lee HW, Lee JI, Kim IH, et al
    Predictive score for hepatocellular carcinoma after hepatitis B eantigen loss in patients treated with entecavir or tenofovir.
    J Viral Hepat. 2020 May 7. doi: 10.1111/jvh.13316.
    PubMed     Abstract available


  270. JEON MY, Lee JS, Lee HW, Kim BK, et al
    Entecavirandtenofoviron renal function in patients with hepatitis B virus related hepatocellular carcinoma.
    J Viral Hepat. 2020 May 4. doi: 10.1111/jvh.13313.
    PubMed     Abstract available


  271. LEE WM, King WC, Schwarz KB, Rule J, et al
    Prevalence and Clinical Features of Patients with Concurrent HBsAg and Anti-HBs: Evaluation of the Hepatitis B Research Network Cohort.
    J Viral Hepat. 2020 May 4. doi: 10.1111/jvh.13312.
    PubMed     Abstract available


  272. PAN YC, Jia ZF, Wang YQ, Yang N, et al
    The role of cesarean section and non-breastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg and HBeAg positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2020 May 3. doi: 10.1111/jvh.13314.
    PubMed     Abstract available


  273. ZHANG M, O'Keefe D, Iwamoto M, Sann K, et al
    High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    J Viral Hepat. 2020 May 2. doi: 10.1111/jvh.13311.
    PubMed     Abstract available


    April 2020
  274. CARRASCO I, Sainz T, Antoinette Frick M, de Ory SJ, et al
    Response to Direct Acting Antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
    J Viral Hepat. 2020 Apr 29. doi: 10.1111/jvh.13308.
    PubMed     Abstract available


  275. CHIU WN, Hung CH, Lu SN, Chen MY, et al
    Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection:a multicenter pooled analysis in Taiwan.
    J Viral Hepat. 2020 Apr 28. doi: 10.1111/jvh.13305.
    PubMed     Abstract available


  276. HONG CY, Sinn DH, Kang D, Paik SW, et al
    Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
    PubMed     Abstract available


  277. YIP TC, Wong VW, Chan HL, Tse YK, et al
    Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13307.
    PubMed     Abstract available


  278. STROFFOLINI T, Ciancio A, Furlan C, Vinci M, et al
    Migratory flow and hepatitis Delta infection in Italy: a new challenge at the beginning of the third millennium.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13310.
    PubMed     Abstract available


  279. CHO JY, Sohn W, Paik YH, Gwak GY, et al
    Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients - functional cure unlikely.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13306.
    PubMed     Abstract available


  280. WANG H, Wang M, Huang J, Xu R, et al
    Novel hepatitis B virus surface antigen mutations associated with occult genotype Bhepatitis B virus infection affect HBsAgdetection.
    J Viral Hepat. 2020 Apr 26. doi: 10.1111/jvh.13309.
    PubMed     Abstract available


  281. LEE J, Park JY, Yang SJ, Lee JY, et al
    Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
    J Viral Hepat. 2020 Apr 17. doi: 10.1111/jvh.13291.
    PubMed     Abstract available


  282. LI YR, Chen WC, Tsai WL, Cheng JS, et al
    Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without anti-viral prophylaxis.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13302.
    PubMed     Abstract available


  283. AMOUGOU-ATSAMA M, Atangana PJA, Noah Noah D, Fewou Moundipa P, et al
    The role of hepatitis C virus genotypes and core mutations inhepatocellular carcinomain Cameroon.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13303.
    PubMed     Abstract available


  284. HUANG X, Young KH, Guo W, Wang Y, et al
    Identification of Hepatitis B virus etiologic antigens, HBx and Pre-S2, in Diffuse Large B-cell Lymphoma.
    J Viral Hepat. 2020 Apr 13. doi: 10.1111/jvh.13301.
    PubMed     Abstract available


  285. ABU FREHA N, Wainstock T, Poupko L, Shemer Avni Y, et al
    Maternal hepatitis B or hepatitis C virus carrier s tatus and long-term infectious morbidity of the offspring: A population-based cohort study.
    J Viral Hepat. 2020 Apr 9. doi: 10.1111/jvh.13300.
    PubMed     Abstract available


  286. DESAI M, White E, Vora N, Gilson R, et al
    High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxis.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13297.
    PubMed     Abstract available


  287. TSENG CW, Wu SF, Chen CY, Ho YC, et al
    Characteristics of Regulatory T Cell Function in Patients with Chronic Hepatitis B and C Coinfection.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13298.
    PubMed     Abstract available


  288. PAN XB
    Reply to the letter by Peng. HBV transmission route among children in China.
    J Viral Hepat. 2020;27:462.
    PubMed    


  289. PENG S
    HBV transmission route among children in China. A letter in response to Young Chinese children without seroprotective hepatitis B surface antibody could be at risk of hepatitis B virus infection through horizontal transmission.
    J Viral Hepat. 2020;27:461.
    PubMed    


    March 2020
  290. DARVISHIAN M, Wong S, Binka M, Yu A, et al
    Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    J Viral Hepat. 2020;27:243-260.
    PubMed     Abstract available


  291. PLATT L, French CE, McGowan CR, Sabin K, et al
    Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.
    J Viral Hepat. 2020;27:294-315.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: